PA
CEROW

Pineridge Advisors’s CERo Therapeutics Warrants CEROW Stock Holding History

Pineridge Advisors’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-150
Closed -$1 – 682
2024
Q3 		$1 Hold
150
– – ﹤0.01% 608
2024
Q2 		$3 Hold
150
– – ﹤0.01% 629
2024
Q1 		$10 Buy
+150
New +$9 ﹤0.01% 605

Other funds holding CEROW

CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Pineridge Advisors's CEROW Position: Q4 2024 in Review

Pineridge Advisors sold out of CERo Therapeutics Warrants (CEROW) in Q4 2024, closing a stake of 150 shares — an estimated $1 sold.

Pineridge Advisors first reported a position in CEROW in Q1 2024 and held it in 3 quarters. The position peaked at $10 in Q1 2024. 26 funds tracked by Wall St. Rank hold CEROW as of Q4 2024.

  • Pineridge Advisors reported no remaining CERo Therapeutics Warrants position as of Q4 2024 after selling out during the quarter.
  • Pineridge Advisors sold 150 CERo Therapeutics Warrants shares in Q4 2024, an estimated $1.
  • Pineridge Advisors first reported a position in CERo Therapeutics Warrants in Q1 2024 and held it in 3 quarters.
  • Pineridge Advisors's CERo Therapeutics Warrants position peaked at $10 in Q1 2024.
  • 26 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2024.

Based on Pineridge Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.